 |
Management and
Corporate Board
James V. Snider, Ph.D.,
President
Dr. Snider joined Critical Diagnostics in August 2005
as President. He is also a member of the board. Prior
to joining CCD he spent over three years as the Executive
Vice President of Business & Operations for IntelligentMD
("IMD"), an early-stage medical device company
that focuses on the essential elements of disease diagnostics
and therapeutic intervention. While at IMD he guided
the company through three rounds of fundraising, staffing
and resourcing for two product development projects
and several business development deals. Prior to joining
IMD, Dr. Snider spent eight years in a series of marketing
and product development positions at Applied Biosystems
(ABI).
Before his tenure at ABI, Dr. Snider was a Senior
Scientist at Biotech Research Laboratories, a contracts
and service research company specializing in retroviral
technologies. Dr. Snider performed his post-doctoral
research as a fellow in the Biological Response Modifiers
Program at the Frederick Cancer Research & Development
Center of the National Cancer Institute. He holds a
BS in chemistry from Grand Valley State University
and a Ph.D. in chemistry from the University of South
Carolina.
David M. Geliebter, Chairman
of the Board and Managing Partner of CCHV
David is a serial entrepreneur with significant experience
successfully starting, growing and selling businesses.
Prior to starting Carrot Capital in 2001, David founded
and ran the Carson Group, one of the world’s
most successful financial information and advisory
companies with over 450 employees and operations around
the world. The company was sold to Thomson Corporation
for $200 million in cash. David was also a founding
principal and President of Evolution Capital, a NASD
broker/dealer subsidiary of Carson and an early-stage
and mezzanine level healthcare investment banking firm.
Before Carson Group, David started and ran another
successful business in the financial services sector:
Harvard Capital. This company was sold to WPP Group
in 1986. He was named Entrepreneur of the Year for
New York in 1993 by Inc. magazine and Ernst & Young.
In addition to Critical Diagnostics David is also the
Chairman of Access Scientific and Remedy Pharmaceuticals, all Carrot Capital-initiated. He sits on the
boards of these companies.
Sven M. Jacobson, Director
of Critical Diagnostics and Principal of CCHV
Sven is a Principal of Carrot Capital. Prior to Carrot,
he was Senior Partner of New Moon Capital, an early-stage
venture capital firm. Sven has a strong operations
background, having lead multinational teams as VP:
E-Commerce of European-based Leisureplanet, and having
served on the board of directors of Rennies (part of
Bidvest Group, one of South Africa’s top 20 listed
companies) where he was responsible for operational
and strategic turnarounds in the Account Management,
Corporate Sales, and Information Systems divisions.
In addition to Critical Diagnostics Sven sits on the
boards of Access Scientific and Remedy Pharmaceuticals, all
Carrot Capital-initiated companies. Sven holds an MBA
and B Sc in Electrical Engineering from WITS University
(South Africa).
Back to top
World-Class
Scientific Advisory Board
(in alphabetical
order)
Donna
J. Edmonds
Donna brings over 30 years of experience in both the
provider and the industry side of the healthcare business. Her
primary focus has been in the introduction, management
and commercialization of new and revolutionary technologies
primarily in critical care areas for patient care.
She has been a Hospital Administrator (Director of
Nursing) and General Manager of a specialty physician
group prior to her recruitment to industry. Her
industry experience includes eight years with Baxter
International in the Alternate Site, Diagnostics and
Cardiovascular groups, the last four as a Vice President
at the group level, where she held positions of increasing
responsibility in Business Development, Sales and Marketing. She
was the Senior Vice President, Market and Business
Development for the Cardiovascular Strategic Business
Unit of Inverness Medical Innovations, a public company
with over $500 million in revenue, following the acquisition
of VC backed Ischemia Technologies in Q1, 2005 where
she held a similar position. In December 2005 she organized
the financing for and became the COO and SVP for Market
Development for VC backed Vital Sensors Inc, which
is commercializing a sensor based cardiac pressure
monitor. She is a Governor-appointed member of the
Virginia Biotech Research Park Authority and a founding
member of the Virginia Biosciences Development Center.
James L. Januzzi, MD
Dr. Januzzi is an Associate Professor of Medicine at
Harvard Medical School, and Physician in the Division
of Cardiology at the Massachusetts General Hospital,
in Boston, where he is also the Chief of the Coronary
Care Unit.
Dr. Januzzi is an active clinical researcher in the
area of cardiac biomarkers, where he has published
ground-breaking research in the optimal applications
of amino-terminal pro-brain natriuretic peptide testing.
In addition, he has published extensively in the areas
of troponin testing, as well as optimal management
of patients with acute coronary syndromes, and acute
aortic syndromes. He has published over 100 peer-reviewed
manuscripts, review articles, and book chapters, and
is on numerous editorial boards for prestigious journals.
He lectures extensively on the value of cardiac biomarker
testing for a broad range of cardiovascular syndromes.
Lastly, Dr. Januzzi has an active cardiology practice,
and serves as the cardiologist to the Boston Red Sox.
Dr Januzzi was the top-ranked graduate of the New York
Medical College in 1994.
Robert
L. Jesse, MD, Ph.D.
Dr. Robert Jesse received his B.S. degree in Biochemistry
from the University of New Hampshire followed by a
PhD in Biophysics at the Medical College of Virginia.
After initially joining the basic sciences faculty
in the Biophysics Department, he then went on to receive
an MD degree followed by Internal Medicine Residency
and Cardiology fellowship at the Medical College of
Virginia campus at Virginia Commonwealth University.
He is presently the Director of Acute Cardiac Care
for Virginia Commonwealth University Health System,
Chairman of the Cardiology Division at the Veteran
Affairs Medical Center in Richmond, and National Program
Director for Cardiology for the Veterans Health Administration
in Washington, DC.
Dr. Jesse, along with the Acute Cardiac Team at VCUHS
pioneered the nationally recognized Chest Pain Program,
which has published widely on both the initial risk
stratification and outcomes for patients with acute
coronary syndromes, especially as related to biomarkers.
Dr. Jesse has been the director of several national
courses on the management of chest pain including the
Society for Chest Pain Centers and Providers 6th Annual
Meeting. He served on the National Academy of Clinical
Biochemistry Task Force that authored the initial Standards
of Laboratory Practice on the use of Cardiac Markers
in 1999, and is presently on the committee rewriting
those guidelines.
Dr. Jesse is a fellow of the American College of Cardiology,
and is a member of the ACC Board of Governors. He is
a fellow of the American Heart Association in both
the Thrombosis, Atherosclerosis, and Vascular Biology
Council and Clinical Cardiology Council, and is currently
the President of the Richmond Metro Chapter of AHA.
Dr Jesse serves on the NIH-NHLBI Advisory Council.
Alan Stewart Maisel, MD
Dr. Maisel is a Professor of Medicine at the University
of California, San Diego as well as the Director of
the Coronary Care Unit and Heart Failure Program at
the VA Medical Center in La Jolla, California. He is
considered a world expert on cardiac biomarkers and
has over 100 scientific publications. Dr. Maisel has
authored several ground-breaking publications which
have paved the way for BNP to become a diagnostic tool
in congestive heart failure. He is active on the faculty
at UCSD where he has won numerous teaching awards.
Dr. Maisel was graduated with a Bachelor of Science
in Psychology from Michigan State University, and was
awarded a Doctor of Medicine degree from the University
of Michigan School of Medicine. Dr. Maisel started
his career at Michael Reese Hospital, where he rose
to Chief Medical Resident. He has held positions as
a Clinical Fellow, Cardiology Section and a Clinical
Investigator at University of California, San Diego;
Associate Investigator for the Veterans Administration
Medical Center; Assistant Professor of Medicine, University
of California San Diego; Director, Heart Station-Veterans
Administration Medical Center; Assistant Professor
of Medicine, University of California, San Diego; Director,
Medical Intensive Care Unit, Veterans Administration
Medical Center; and Associate Professor of Medicine,
University of California, San Diego.
David A. Morrow, MD, MPH
Dr. Morrow is a clinical investigator with the TIMI
Study Group (a series of trials on improved treatments
for coronary disease), and an Associate Physician
in the Division of Cardiovascular Medicine at Brigham
and Women's Hospital, Boston, MA. Dr. Morrow earned
his medical degree from Harvard Medical School and
a Masters in Public Health with a concentration in
clinical study design and interpretation from the
Harvard School of Public Health. He is currently
an Assistant Professor of Medicine at Harvard Medical
School. Dr. Morrow is an active investigator in the
TIMI Study Group with a research focus on management
of acute coronary syndromes, risk stratification
in coronary artery disease and the clinical evaluation
of novel biomarkers. He has been a major contributor
to the development and expansion of the TIMI Study
Group Biomarker Program. He sits on the National
Academy of Clinical Biochemistry (NACB) Laboratory
Medicine Practice Guidelines Committee on Biochemical
Cardiac Markers for which he leads the clinical section
on acute coronary syndromes. He also serves on the
Program Committee of the Council on Clinical Cardiology
of the American Heart Association and is on the Board
of Editors for the journals Circulation and Clinical
Chemistry. Dr. Morrow has more than 75 original scientific
reports, reviews, editorials, book chapters and electronic
publications in his areas of expertise.
William Franklin Peacock IV,
MD, FACEP
Dr. Peacock received his MD from Wayne State University
in 1985 and completed his internship and residency
in emergency medicine at William Beaumont Hospital
in Michigan. After his training, he was attending staff
at William Beaumont Hospital, and at the University
of Michigan where he was an Assistant Professor. Ultimately,
he was the Emergency Medicine Associate Residency Director
at William Beaumont Hospital. In 1994, Dr. Peacock
moved to Cleveland Ohio to assist in the development
of a new department of emergency medicine at The Cleveland
Clinic, where he is currently the Vice Chief of Emergency
Medicine. He is also an Associate Professor at The
Ohio State University, as well as the Medical Director
for Event Medicine, which provides care to the stadiums
of the Cleveland Browns, Cleveland Indians, and the
Cleveland Gund Arena.
Dr. Peacock's academic focus has been in the research
of emergency cardiology, where he has actively pursued
the development and application of novel technologies
for rendering care to emergency department patients.
He has over 100 publications and has received substantial
research grants in the areas of acute coronary syndromes
and in heart failure management. In 2004, he received
the "Award for Best Paper" at the Research
Forum of the American College of Emergency Physicians.
Recently, he was an integral member of the medical
team that received the Codman Award in recognition
for improvement in the delivery of care to heart failure
patients. He is currently a member of the editorial
board of the journal Congestive Heart Failure, and was
a past editor of the case report section in the journal "Topics
in Emergency Medicine".
Dr. Peacock is a fellow of the American College of Emergency
Physicians, and among other offices, served as a member
of the Board of Directors for the Michigan College of
Emergency Physicians. He is also a member in the American
Academy of Emergency Medicine, and the Society of Academic
Emergency Medicine. He is a founding member of the Society
of Chest Pain Centers and Providers, where he is the
current chairman of the Heart Failure Educational Track
for Annual Congress. He is also an active member in the
Heart Failure Society of America and the American Heart
Association, as well as many other professional organizations.
Alan Wu, Ph.D., D.A.B.C.C.
Alan H.B. Wu, Ph.D., is Chief of Clinical Chemistry
and Toxicology at San Francisco General Hospital
and Professor of Laboratory Medicine, University
of California, San Francisco. Dr. Wu's research interest
has been in the fields of biochemical markers for
cardiovascular disease including CK-MB, myoglobin,
troponin, B-type natriuretic peptide, markers of
myocardial ischemia, and stroke. He has published
over 300 papers, abstracts, and book chapters in
this field. He is author of Cardiac Markers,
Totowa Press, 1st and 2nd edition (1999 and 2003).
He is a member of the National Academy of Clinical
Biochemistry Laboratory Medicine Practice Guideline
Committees on "Recommendations for the Use of
Cardiac Markers in Coronary Artery Diseases." Dr.
Wu has served on several editorial boards including Clinical
Chemistry, Annals of Clinical Laboratory
Science, Point of Care, and since 1998,
he is co-editor-in-chief for Clinica Chimica
Acta. He is a member of the AACC Standardization
subcommittees on CK-MB and cardiac troponin, and
the International Federation of Clinical Chemistry
Standardization of Markers of Cardiac Damage Committee.
Dr. Wu received B.S. degrees in chemistry and biology
at Purdue University, West Lafayette, Indiana, and
a Ph.D. degree in analytical chemistry at the University
of Illinois, Champaign-Urbana, Illinois. He completed
a postdoctoral fellowship in clinical chemistry at
Hartford Hospital. He is certified by the American
Board of Clinical Chemistry in Clinical Chemistry
and Toxicological Chemistry.
Back to top |
|
